MedPath

Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility

Not Applicable
Completed
Conditions
Ovarian Cancer
Breast Cancer
Interventions
Behavioral: Print DA
Behavioral: Inconclusive Results DA
Behavioral: Enhanced Print DA
Behavioral: Internet DA
Behavioral: Enhanced Internet DA
Registration Number
NCT02133703
Lead Sponsor
Georgetown University
Brief Summary

This non-therapeutic trial is for women who have received results of genetic testing for BRCA1/2 mutations. The trial compares decision support tools designed to facilitate informed decision making regarding risk management following testing to usual care. The researchers will test separate decision support tools for women who receive positive test results and women who receive negative/inconclusive test results. Among women who receive a positive test result, an interactive decision support intervention will be compared to a print intervention. Among women who receive an inconclusive result, an interactive intervention will be compared to usual care.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
369
Inclusion Criteria
  • Undergo BRCA1/2 genetic counseling and testing at one of four study sites
  • Receive positive or uninformative test results
  • English speaking
Exclusion Criteria
  • Newly diagnosed breast cancer patients who have not yet initiated definitive breast cancer treatment
  • Previous bilateral mastectomy

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Mutation Carrier: Print DAPrint DABRCA1/2 carriers randomized to this arm will receive a print decision aid without a preference clarification tool.
Inconclusive Results: DAInconclusive Results DAParticipants who receive inconclusive results who are randomized to this arm will have access to an Internet decision tool designed to facilitate management decision making
Mutation Carrier: Enhanced Print DAEnhanced Print DABRCA1/2 carriers randomized to this arm will be sent a print-based decision aid with a print preference clarification tool.
Mutation Carrier: Internet DAInternet DABRCA1/2 carriers randomized to this arm will have access to Internet-based decision support intervention without a preference clarification tool.
Mutation Carrier: Enhanced Internet DAEnhanced Internet DABRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool.
Primary Outcome Measures
NameTimeMethod
Decision Satisfaction12-months post-randomization

Satisfaction with Decision Scale

Psychological Distress1-month post randomization
Decision Conflict1-month post-randomization

Decisional Conflict Scale

Knowledge1-month post randomization

Knowledge of risk management options.

Health Related Quality of Life12-months post randomization

SF-12

Utilization of breast and ovarian cancer risk management options12-months post-randomization

We will assess uptake of the following risk management strategies:

1. Risk reducing surgery (mastectomy and oophorectomy)

2. Chemoprevention

3. Breast and ovarian cancer screening

Secondary Outcome Measures
NameTimeMethod
Knowledge3-months post randomization

Knowledge of risk management options

Psychological Distress3-months post-randomization
Decisional Conflict3-months post-randomization

Decisional Conflict Scale

Trial Locations

Locations (1)

Georgetown University Medical Center/Lombardi Comprehensive Cancer Center

🇺🇸

Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath